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Abstract – Robust, novel information on tumor 
microenvironment would improve therapeutic follow-up 
in oncology. Shear wave elastography (SWE) evaluates 
Young’s modulus (stiffness) based on shear wave velocity. 
Dynamic contrast-enhanced ultrasound (CEUS) traces 
microvascular flow with intravascular microbubbles. In 
this study, an ectopic tumor model was modified using 
two different types of drugs a cytotoxic 
(cyclophosphamide) and an anti-angiogenic (sunitinib). 
Both CEUS and SWE imaging were sensitive to 
functional, physiological and mechanical modifications of 
the tumor and provided complementarity information to 
describe these modifications. 
 
Keywords – Therapy monitoring, Contrast-Enhanced 
Ultrasound, Shear Wave Elastography, Tumor 
microenvironment. 
  
I. INTRODUCTION 
 
Solid tumors are comprised of cancer cells and stromal cells 
embedded in an altered extra-cellular matrix (ECM) and fed 
by a vascular network. Hypoxic regions of tumors and the 
tumor microenvironment (TME) can provoke the expression 
of HIF!-factor which initiates synthesis of growth factors such 
as VEGF, PDGF, FGF implicated in neovascularization [1]. In 
vivo follow-up of TME modifications will increase 
understanding of mechanisms underlying tumor development. 
For example, the functional properties of the new 
microvascular network can be quantified by contrast-enhanced 
ultrasound CEUS (contrast agent remains in vascular 
compartment) [2] and the formation of necrosis and fibrosis in 
the tumor can be assessed by SWE [3]. Our goal was to 
evaluate sensitivity and complementarity for dynamic 
contrast-enhanced ultrasound (CEUS) and shear wave 
elastography (SWE) to modifications of the TME during 
cytotoxic and antiangiogenic therapies in ectopic, murine 
Lewis Lung Carcinoma (LLC) tumors. The cytotoxic drug 
(cyclophosphamide) prevents cancer-cell duplication. The 
antiangiogenic drug (sunitinib) effects the TME by inhibiting 
several receptors involved in tumor vascularization. 
Modifications detected by imaging were compared to 
modifications in the TME (fibrosis and necrosis).  
 
II. MATERIALS & METHODS 
 
II.1. Pre-clinical tumor model & therapies  
Lewis Lung Carcinoma (LLC) fragments (20-40 mm
3
) were 
implanted in the right flank of 7-week-old female mice. 
Three groups were defined, a group of 24 mice were treated 
with sunitinib (antiangiogenic). Another of 26 mice were 
treated with cyclophosphamide (cytotoxic) and a placebo 
group with 26 mice was treated only with drug vehicle. Six 
days after implantation of fragments, sunitinib was 
administrated orally at a concentration of 40mg/kg/day and 
cyclophosphamide was administrated by intraperitoneal 
injection at a concentration of 150mg/kg for 3 days.  
 
II.2. Shear Wave Elastogdraphy (SWE) 
SWE measurements were carried out with a clinical 
ultrasound system (Aixplorer, SuperSonic Imagine) using an 
SL15-4 probe with a bandwidth of 4-15MHz and a central 
frequency around 8 MHz. For each tumor, SWE data were 
acquired from 3 independent planes along both the 
longitudinal and transverse directions (6 SWE measurements 
per tumor). Data were acquired using penetration mode with 
a color scale ranging from 0 to 50 kPa.  
 
II.3. CEUS & data processing  
Contrast imaging was performed with another clinical 
ultrasound system (Sequoia 512; Siemens) with a broadband 
7-14 MHz transducer in cadence contrast pulse sequencing 
mode. A commercially available contrast agent, SonoVue
TM
, 
was used. Regions with no contrast-enhancement were then 
excluded and the echo-power from the perfused region was 
measured [4]. A lognormal bolus model was fit to the 
resulting echo-power curve.  
 
Figure 1: Functional parameters extracted from perfused area. 
 
Several perfusion parameters were estimated (Fig. 1): peak-
enhancement (PE), mean transit time (MTT), wash-in and 
washout rates (WIR, WOR). CEUS was followed for 13 days 
from the initiation of cytotoxic (N=16), anti-angiogenic 
(N=16), and placebo (N =18) therapy. 
 
II.4. Immunohistochemistry 
Blind evaluation of histological slides was made by a 
pathologist with 12 years of experience. Tumors that were 
not used for other analysis were prepared for histology at the 
end of follow-up study (Day 13). Thus, percentage of 
necrosis and fibrosis were assessed with HES and Red Sirius 
staining respectively for: 8 tumors in the cytotoxic group, 14 
in the anti-angiogenic group and 19 in the placebo group.  
 
III. RESULTS 
 
Tumor volumes are summarized in Figure 2. From Day 3 
after the beginning of therapy, tumor volume of the cytotoxic 
group (20 ± 10mm
3
) was significantly lower compared to 
both the anti-angiogenic (42 ± 24mm
3
, p=0.02) and the 
placebo (37 ± 16 mm
3
, p=0.003) groups. This difference was 
maintained throughout the follow-up to Day 13. The tumor 
volume of the placebo group was only significantly higher 
than for the anti-angiogenic group (p=0.046) on Day 13.  
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Figure 2: Tumor volume estimated for an ellipsoid with axes 
lengths equal to measurements made along the longitudinal, 
transversal and thickness of the tumor.  
 
SWE measurements are shown in Figure 3. From Day 7 after 
the beginning of therapy, tumor stiffness for the anti-
angiogenic group (14.1 ± 3.6 kPa) was significantly higher 
than for the cytotoxic group (9.8 ± 2.8 kPa, p<0.005) and the 
placebo group (12.0 ± 2.4 kPa, p=0.002). Differences 
remained significant from Days 7 to 13 (anti-angiogenic vs. 
cytotoxic, p=0.003; vs. placebo, p=0.002).  
Figure 3 shows the percentage of the unperfused area in the 
tumor determined with CEUS. This percentage is 
significantly higher for the anti-angiogenic group at Day 13 
(29 ± 21 %) compared to the cytotoxic (7.3 ± 15 %, p=0.004) 
and placebo (7.5 ± 13 %, p=0.002) groups.  
The percentage of necrosis and fibrosis as assessed by 
histology on Day 13 are presented in Figure 3. The level of 
necrosis and fibrosis, respectively, in the anti-angiogenic 
group (n=14, HES = 20.5 ± 11.3 %; Sirius red = 14.5 ± 9.9 %) 
is significantly higher than in the cytotoxic (n=8, HES = 7.8 ± 
5.3 %, p=0.01; Sirius red = 5.6 ± 5.0 %, p=0.04) and the 
placebo (n=19, HES = 7.6 ± 5.5 %, p=0.0004; Sirius red = 6.4 
± 6.9 %, p = 0.01) groups.  
 
Figure 3: In vivo (SWE, CEUS) and ex vivo (necrosis and 
fibrosis) quantification of biomarkers. Cytotoxic group in 
purple, antiangiogenic group in orange and placebo group in 
green. Wilcoxon test 
 
IV. DISCUSSION & CONCLUSION 
 
Longitudinal follow-up of tumor modifications was 
performed in vivo using CEUS, SWE and ex vivo with 
immunohistochemistry. One of the main objectives was to 
understand how the two imaging modalities reflect changes 
in the tumor produced by a cytotoxic drug 
(cyclophosphamide) vs. changes in the TME produced by an 
anti-angiogenic drug (sunitinib).  
The high mean stiffness of tumors in the anti-angiogenic 
group compared to the others is associated with a higher 
proportion of fibrosis (Figure 3). This is consistent with 
results described by Chamming’s et al [3] showing a very 
significant correlation between stiffness and percentage of 
fibrosis (Spearmans correlation test, ! ! !!!", p<0.0001). 
At Day 13, the percentage of both necrosis and fibrosis of the 
anti-angiogenic group (20.5 ± 11.3 %; 14.5 ± 9.9 %, 
respectively) is significantly higher than for cytotoxic (7.8 ± 
5.3 %, p=0.01; 5.6 ± 5.0 %, p=0.04) and placebo groups (7.6 
± 5.5 %, p=0.0004; 6.4 ± 6.9 %, p=0.01). At the same time 
during therapeutic follow-up, the percentage of unperfused 
area is significantly higher in the anti-angiogenic group (29 ± 
21 %) compared to the cytotoxic (7.3 ± 15 %, p=0.004) and 
placebo groups (7.5 ± 13 %, p=0.002).  
Table 1 summarizes the % variation of each measured 
parameter from the start to the end of therapy. During 
cytotoxic therapy, only the SWE was significantly modified.  
The variation of tumor stiffness for the cytotoxic group was 3 
to 4 times lower than that for other groups.  
 
!"#$#$%&'( )*#&+,*-&$-.*&'( /0,'.1$(
!"#2( $%&"'()** !"#+* $%&"'()* !"#+* $%&"'()*
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/5( %2/6* -/25,* %12.* 3-/---4* %72.* 3-/--8*
467( %05* -/41,* %20.* 3-/---4* %62.* 3-/---4*
487( %-/,* -/878* %61.* 3-/---4* %71.* 3-/--4*
9::( 4/4* -/18-* 48.* 3-/--8* 46.* 3-/--8*
 
Table 1: Variation between baseline and Day 13 of mean 
values of each parameter for each group. P-values were 
calculated using a Wilcoxon signed-rank paired test. Asterisks 
indicate that the variation from baseline values was 
significant. 
 
Between the baseline and Day 13, no significant variation of 
the mean value of functional parameters (PE, WIR, WOR, 
MTT) was observed for the cytotoxic group whereas all the 
functional parameters for the anti-angiogenic and placebo 
group underwent significant variations. For anti-angiogenic 
and placebo groups, the variation of all parameters, SWE 
included, between baseline and Day 13 were strongly 
significant (Table 1). As expected, the anti-angiogenic drug 
strongly reduced vascularization in term of vascular 
distribution (unperfused area, Fig 3) and functionality (Table 
1). 
Finally, modifications of parameters observed with CEUS 
were associated with changes in the flow and distribution in 
the functional microvessels. Modifications of the SWE are 
consistent with modifications observed in other models 
associated with development of fibrosis but additional 
histological evaluation is needed to confirm this correlation in 
our tumor model. Combining these imaging modalities could, 
therefore, be useful to more completely monitor both the 
structural and vascular effects of cytotoxic and anti-angiogenic 
therapies.  
 
REFERENCES 
[1] S. M. Weis and D. a Cheresh, “Tumor angiogenesis: molecular 
pathways and therapeutic targets.,” Nat. Med., vol. 17, no. 11, 
pp. 1359–70, Jan. 2011. 
[2] M. Lamuraglia et al. “Clinical relevance of contrast-enhanced 
ultrasound in monitoring anti-angiogenic therapy of cancer: 
current status and perspectives.,” Crit. Rev. Oncol. Hematol., 
vol. 73, no. 3, pp. 202–12, Mar. 2010. 
[3] F. Chamming’s et al. “Shear wave elastography of tumour 
growth in a human breast cancer model with pathological 
correlation.,” Eur. Radiol., vol. 23, no. 8, pp. 2079–86, Aug. 
2013. 
[4] T. Payen et al. “Echo-power estimation from log-compressed 
video data in dynamic contrast-enhanced ultrasound imaging.,” 
Ultrasound Med. Biol., vol. 39, no. 10, pp. 1826–37, Oct. 2013.  
SESSION IMAGERIE ET THÉRAPIE PAR ULTRASONS
